FDA Investigating Reports of Alopecia and Suicidal Ideation as Possible Weight-Loss Drug Side Effects

The FDA is also investigating reported side effects of aspiration.

Boxes of the diabetes drug Ozempic rest on a pharmacy counter in Los Angeles, California, on April 17, 2023. Mario Tama/Getty Images

The U.S. Food and Drug Administration (FDA) is investigating whether three potential health issues or side effects, including suicidal ideation, hair loss, and aspiration, are linked to popular semaglutide and tirzepatide weight-loss drugs like Ozempic, Wegovy, and Mounjaro.

The investigation was unveiled on Tuesday with the agency’s quarterly report, which revealed that the FDA is looking into reports of the alleged side effects and if there is a need for regulatory action.